Brokerages forecast that bluebird bio, Inc. (NASDAQ:BLUE) will report earnings of ($1.68) per share for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for bluebird bio’s earnings. The lowest EPS estimate is ($2.68) and the highest is ($0.95). bluebird bio reported earnings of ($3.01) per share in the same quarter last year, which indicates a positive year over year growth rate of 44.2%. The firm is scheduled to announce its next quarterly earnings results on Tuesday, February 22nd.
On average, analysts expect that bluebird bio will report full-year earnings of ($11.14) per share for the current fiscal year, with EPS estimates ranging from ($11.53) to ($10.74). For the next year, analysts forecast that the business will report earnings of ($5.78) per share, with EPS estimates ranging from ($11.14) to ($1.90). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research firms that cover bluebird bio.
bluebird bio (NASDAQ:BLUE) last released its quarterly earnings data on Friday, November 5th. The biotechnology company reported ($3.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.65) by ($0.51). bluebird bio had a negative net margin of 1,610.78% and a negative return on equity of 76.93%. The company had revenue of $22.70 million for the quarter, compared to analysts’ expectations of $39.07 million. During the same period last year, the company posted ($2.94) EPS. The business’s revenue for the quarter was up 17.6% compared to the same quarter last year.
Large investors have recently added to or reduced their stakes in the business. Berman Capital Advisors LLC lifted its stake in shares of bluebird bio by 3,217.0% in the third quarter. Berman Capital Advisors LLC now owns 1,758 shares of the biotechnology company’s stock worth $33,000 after buying an additional 1,705 shares in the last quarter. Lazard Asset Management LLC lifted its position in bluebird bio by 4,861.3% in the 2nd quarter. Lazard Asset Management LLC now owns 3,076 shares of the biotechnology company’s stock valued at $97,000 after acquiring an additional 3,014 shares in the last quarter. Point72 Hong Kong Ltd boosted its stake in bluebird bio by 130.5% during the 3rd quarter. Point72 Hong Kong Ltd now owns 6,474 shares of the biotechnology company’s stock valued at $124,000 after purchasing an additional 3,665 shares during the last quarter. Ameritas Investment Partners Inc. bought a new stake in shares of bluebird bio in the 2nd quarter worth $169,000. Finally, AGF Investments Inc. purchased a new position in shares of bluebird bio in the third quarter worth $199,000. Institutional investors and hedge funds own 77.66% of the company’s stock.
bluebird bio stock traded up $0.03 during trading hours on Thursday, reaching $10.76. The stock had a trading volume of 4,614,857 shares, compared to its average volume of 1,633,104. The stock has a market cap of $754.35 million, a PE ratio of -0.84 and a beta of 1.58. The company has a fifty day simple moving average of $17.80 and a 200-day simple moving average of $23.38. bluebird bio has a 52 week low of $10.21 and a 52 week high of $53.68.
bluebird bio Company Profile
bluebird bio, Inc is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217.
Featured Article: How is a Moving Average Calculated?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.